Cargando…

Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data

PURPOSE: To date, ovarian cancer screening in asymptomatic women has not shown a mortality benefit. The aim of this simulation study was to outline the impact of different histological subtypes on a potential stage-shift, achieved by screening. METHODS: Real-world data were derived in the period of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinkasserer, Lena, Irmgard, Delmarko, Weiss, Tatjana, Dirschlmayer, Walter, Mossig, Michael, Zeimet, Alain G., Marth, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782802/ https://www.ncbi.nlm.nih.gov/pubmed/34125280 http://dx.doi.org/10.1007/s00404-021-06117-4

Ejemplares similares

Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center
por: Zang, Benedikt, et al.
Publicado: (2022)

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
por: Drew, Yvette, et al.
Publicado: (2019)

Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis
por: Steinkasserer, L., et al.
Publicado: (2022)

Multi-Institutional Trends in Gynecological Robotic Surgery in India: A Real-World Scenario
por: Sinha, Rooma, et al.
Publicado: (2023)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer
por: Luger, Anna K., et al.
Publicado: (2020)

A comparison of four technologies for detecting p53 aggregates in ovarian cancer
por: Heinzl, Nicole, et al.
Publicado: (2022)

The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective
por: Knoll, Katharina, et al.
Publicado: (2021)

Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer: a case–control study
por: Berner, Kai, et al.
Publicado: (2021)

Certification as dysplasia unit and its impact on large loop electrosurgical excision (LEEP)
por: Hanczuk, Tatjana, et al.
Publicado: (2022)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas
por: Zhan, Xiangbo, et al.
Publicado: (2019)

The sL1CAM in sera of patients with endometrial and ovarian cancers
por: Wojciechowski, Michał, et al.
Publicado: (2016)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Incidence and predictors for chemotherapy modifications and their impact on the outcome of ovarian cancer patients
por: Hatsy, Sandra, et al.
Publicado: (2022)

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue
por: Peters, Inge T. A., et al.
Publicado: (2016)

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

The role of resveratrol, Sirtuin1 and RXRα as prognostic markers in ovarian cancer
por: Chen, Fangfang, et al.
Publicado: (2021)

Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors
por: Wang, Lifei, et al.
Publicado: (2022)

Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors
por: Moszynski, Rafal, et al.
Publicado: (2013)

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
por: Zhao, Chuchu, et al.
Publicado: (2017)

Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases
por: Chen, Junyu, et al.
Publicado: (2021)

GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1
por: Ning, Xin, et al.
Publicado: (2022)

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
por: Grill, Sabine, et al.
Publicado: (2020)

Prostatic tissue: an unexpected finding in a mature ovarian teratoma: Case report and systematic literature review
por: Pecorella, Irene, et al.
Publicado: (2021)

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
por: Reuter, Susanne, et al.
Publicado: (2021)

Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience
por: Costantini, Barbara, et al.
Publicado: (2022)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Successful management of mucinous ovarian cancer by conservative surgery in week 6 of pregnancy: case report and literature review
por: He, Shan-yang, et al.
Publicado: (2012)

MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Ovarian teratoma-associated anti-NMDAR encephalitis: a single-institute series of six patients from China
por: Yu, Minhua, et al.
Publicado: (2020)

The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer
por: Rawert, Friederike Luise, et al.
Publicado: (2022)

A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
por: Arezzo, Francesca, et al.
Publicado: (2022)

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
por: Hall, Marcia, et al.
Publicado: (2019)

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review
por: Huber, D., et al.
Publicado: (2020)

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
por: Pignata, Sandro, et al.
Publicado: (2021)

Status of Surgical Management of Borderline Ovarian Tumors in France: are Recommendations Being Followed? Multicentric French Study by the FRANCOGYN Group
por: Lecointre, Lise, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8bvh20di40t19h5cpt5cojd1a2